Homburger advises ADC Therapeutics in its follow-on public offering in the United States

ADC Therapeutics, a Swiss-based late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates, announced the pricing of its upsized follow-on public offering of shares in the United States, thus raising gross proceeds of USD 204 m. In addition, certain existing shareholders had granted the underwriters an option to purchase additional sharesfor an aggregate amount of up to USD 30.6 m.

The team

Homburger advises ADC Therapeutics in this transaction. The team is led by partner Dieter Gericke (Corporate/M&A) and includes lead associate Daniel Häusermann (Corporate/ M&A), partners Reto Heuberger (Tax) and Benjamin Leisinger (Banking and Finance), as well as associates Olivier Baum (Banking and Finance), Estelle Piccard (Corporate/M&A) and Marc Vogelsang (Tax).

Homburger advises ADC Therapeutics in its follow-on public offering in the United States



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram